



## **FOR IMMEDIATE RELEASE**

### **Contacts:**

Bob Hebert  
Chief Financial Officer  
CPEX Pharmaceuticals, Inc.  
603.658.6100  
[rhebert@cpepharm.com](mailto:rhebert@cpepharm.com)

Christine Labaree  
The Trout Group  
617.583.1307  
[clabaree@troutgroup.com](mailto:clabaree@troutgroup.com)

## **CPEX Pharmaceuticals to Present at Ninth Annual Diabetes Technology Meeting**

**Exeter, NH, September 15, 2009** – CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) (“CPEX”) today announced that it will participate in the Ninth Annual Diabetes Technology Meeting to be held November 5–7, 2009, at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to present an oral presentation titled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7, 2009.

In addition, CPEX recently completed its data analyses on four Phase 1 studies which have been accepted for poster presentations at the meeting. The posters, “A Randomized 6-Way Crossover Study of Nasulin™, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing”, “Two Randomized Crossover Glucose Clamp Studies of Nasulin™ and Lispro”, “Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (Nasulin™)” and “Dose-Exposure for Two Dose Strengths of Nasal Insulin (Nasulin™)” will be displayed during the Poster Presentation Sessions of the meeting on Thursday and Friday, November 5 and 6, 2009.

The Diabetes Technology Meeting is the second largest scientific diabetes meeting in the United States, after the American Diabetes Association’s annual Scientific Sessions meeting. Clinicians, industry leaders, and regulatory experts from all over the world attend this conference each year. This event is the only scientific meeting in the world that focuses on the engineering, regulatory, clinical, and business aspects of emerging diabetes devices for: measuring glucose and other analyses; delivering insulin and other metabolic peptides; transmitting physiological data; increasing adherence to therapy; and closing the loop for automated treatment of diabetes. The meeting is presented by the Diabetes Technology Society in cooperation with Centers for Disease Control, U.S. Army, National Space Biomedical Research Institute, University of California at Berkeley, the Georgia Tech/Emory Center for Engineering of Living Tissues, and Mills-Peninsula Health Services.

### **About CPEX Pharmaceuticals**

CPEX Pharmaceuticals, Inc is an emerging specialty pharmaceutical company focused on the development, licensing and commercialization of pharmaceutical products utilizing CPEX’s validated drug delivery platform technology. CPEX has U.S. and international patents and other

proprietary rights to technology that facilitates the absorption of drugs. CPEX has licensed applications of its proprietary CPE-215<sup>®</sup> drug delivery technology to Auxilium Pharmaceuticals, Inc. which launched Testim<sup>®</sup>, a topical testosterone gel, in 2003. CPEX is also developing a proprietary intranasal insulin product candidate, Nasulin<sup>™</sup>, which is currently in Phase 2 clinical trials. CPEX maintains its headquarters in Exeter, NH. For more information about CPEX, please visit [www.cpexpharm.com](http://www.cpexpharm.com).